Related Experiment Video

Updated: Jul 18, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

The role of death receptor ligands in shaping tumor microenvironment

Theresa L Whiteside1

  • 1Department of Pathology, Immunology and Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. whitesidetl@upmc.edu

Immunological Investigations
|December 28, 2006
PubMed

Insights

Tumor cells use death ligands like FasL and TRAIL to evade immune responses. These ligands can trigger both cell death and inflammation, promoting tumor growth and survival.

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • Death receptor ligands (FasL, TRAIL) induce apoptosis but also pro-inflammatory signals.
  • Tumor-associated FasL mediates "Fas counterattack" against immune cells.
  • NF-kappaB activation by death ligands links inflammation and cancer.

Purpose of the Study:

  • To explore the dual role of death ligands in cancer immunity.
  • To understand how tumors escape immune surveillance using death ligands.
  • To highlight NF-kappaB's role in regulating death ligand activities.

Main Methods:

  • Analysis of death receptor ligand signaling pathways.
  • Investigation of NF-kappaB activation in the tumor microenvironment.
  • Review of molecular mechanisms underlying tumor immune evasion.

Main Results:

  • Death ligands exhibit dual functions: apoptosis induction and pro-inflammatory signaling.
  • Tumor-associated FasL can inhibit immune cell apoptosis and promote inflammation.
  • NF-kappaB activation by death ligands leads to cytokine production and tumor growth.

Conclusions:

  • Tumors exploit death ligands for immune evasion.
  • NF-kappaB is a critical regulator of death ligand dual activities in cancer.
  • Death ligands represent a key strategy for tumor escape from immune control.

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.